The Korean patent will cover important market applications of multi- protocol RFID-enabled cell phones such as allowing consumers to read disposable wireless diagnostic skin patches, including glucose.
The patent also will cover reading RFID immunoassays for Point of Care (POC) or home-based advanced diagnostics using cell phones. RFID immunoassays can be used for many key market applications such as trace analysis of contaminants in foods, pathogen detection, etc. Other diagnostic applications for cell phones are also covered.
"The allowance of this patent in Korea is an important milestone in our vision to create low cost consumer-based cell phone-sensor networks and revolutionize diagnostics worldwide," announced Dr. John P. Peeters, the founder of Gentag. "We look forward to working with our partners to bring this technology to market as soon as possible."
The newly allowed patent is owned by Altivera, LLC, a Gentag operated and managed company.
Related Links:
